Market Place
Sourcing Support
Immutep Reports Successful FDA Meeting On Phase III NSCLC Trial Design
22 Jul 2024 //
GLOBENEWSWIRE
Immutep Reports Positive Results In First Line Head And Neck Cancer
11 Jul 2024 //
GLOBENEWSWIRE
Immutep To Present Clinical Results At ESMO Virtual Plenary And Host Webcast
03 Jul 2024 //
GLOBENEWSWIRE
Commercial Manufacturing of Eftilagimod at 2000L Scale Granted Authorization
21 Sep 2023 //
GLOBENEWSWIRE
TACTI-002 Data Show Antitumor Activity With Second-Line Eftilagimod Alpha
01 Sep 2023 //
ONCLIVE
Immutep Efti in Combination with Pembrolizumab Achieves Benefit in 1L NSCLC
17 May 2023 //
GLOBENEWSWIRE
Immutep Receives Approval to Initiate INSIGHT-005 Trial Eftilagimod Alpha
01 May 2023 //
GLOBENEWSWIRE
Immutep Successfully Achieves Commercial Scale in MFG of Eftilagimod Alpha
08 Dec 2022 //
GLOBENEWSWIRE
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3
09 Nov 2022 //
GLOBENEWSWIRE
Immutep Receives FDA Fast Track Desig for LAG-3 Therapeutic Eftilagimod Alpha
04 Oct 2022 //
GLOBENEWSWIRE
Immutep provides clinical development update for its first-in-class LAG-3 APC
15 Sep 2022 //
PHARMABIZ
Immutep Announces Investigator-Initiated PhasII Trial LAG-3 Eftilagimod Alpha
06 Sep 2022 //
GLOBENEWSWIRE
Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein
30 Aug 2022 //
GLOBENEWSWIRE
Immutep completes patient enrollment in phase II TACTI-002 study
22 Nov 2021 //
PHARMABIZ
Immutep Granted Chinese Patent for Eftilagimod Alpha
15 Nov 2021 //
BIOSPACE
Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
31 Aug 2021 //
GLOBENEWSWIRE
FDA Grants Fast Track Status to Eftilagimod Alpha for Frontline
08 Apr 2021 //
ONCLIVE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.